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In the past few decades, the anticoagulants heparin and
warfarin have been crucial in the prevention and treatment
of venous and arterial thromboembolism. However, both
drugs have signiﬁcant limitations, including adverse reactions
such as immune-mediated thrombocytopenia with heparin and
microvascular thrombosis with warfarin [1]. As a result, new
anticoagulants have been sought with high afﬁnity and
speciﬁcity for thrombin. Among these, a number of analogs
of hirudin have been synthesized, of which only bivalirudin is
currently marketed.
Bivalirudin is a small polypeptide (2180 Da), comprising of
20 amino acids (D-Phe–Pro–Arg–Pro–Gly–Gly–Gly–Gly–
Asn–Gly–Asp–Phe–Glu–Glu–Ile–Pro–Glu–Glu–Tyr–Leu). The
N-terminal D-Phe–Pro–Arg–Pro region binds with high afﬁnity
to the active site of thrombin and the C-terminal Asn–Gly–
Asp–Phe–Glu–Glu–Ile–Pro–Glu–Glu–Tyr–Leu dodecapeptide
binds to the ﬁbrinogen-binding region of thrombin. Through
this dual mechanism of action, bivalirudin acts as a short acting
reversible thrombin inhibitor which has been approved for
percutaneous coronary intervention (PCI) and acute coronary
syndromes (ACSs) [2].
Most previous studies of bivalirudin have focused on its
pharmacodynamic properties in a variety of clinical settings
[3–6]. In contrast, reports of pharmacokinetic studies and the
analytical methods required to support them are sparse.
Farthing et al. [7] used liquid chromatography with ﬂuores-
cence detection to quantitate bivalirudin in human plasma and
urine but the method involved a time consuming derivatiza-
tion step and with a lower limit of quantiﬁcation (LLOQ) of
3 mg/mL, was relatively insensitive. Robson et al. [8] were the
ﬁrst to report a method based on liquid chromatography–
tandem mass spectrometry (LC–MS/MS) with linear range of
0.5–25 mg/mL, also with relatively high LLOQ. Recently, Pan
et al. [9] developed a sensitive LC–MS/MS method with
LLOQ 1.25 ng/mL, but the gradient eluting chromatographic
condition required a relatively long cycle time (7 min), and it
also suffered from complicated and time-consuming (about
40 min) sample preparation, thus the total time for testing a
sample was about 1 h from sample preparation to detection.
In view of these limitations, we have developed a rapid and
highly sensitive LC–MS/MS method for quantitation of
bivalirudin in human plasma which combines simple sample
preparation with high sensitivity (1 ng/mL), isocratic elution, a
short run time (3.5 min). Moreover, this method only needs a
small volume (100 mL) plasma, compared with relatively large
volume (200 mL) reported by Pan et al. [9], which greatly
reduces the distress and improves the compliance of volunteers
in the process of blood samples collection. This rapid method
shows high sample throughput (15 min for one sample
preparation and 3.5 min for detection, indicating that morethan 150 samples could be assayed daily) making it eminently
suitable for large batches of biological samples in clinical
pharmacokinetic studies. The assay was fully validated includ-
ing an assessment of the adsorption of bivalirudin to poly-
propylene vials and was shown to be suitable for clinical
pharmacokinetic studies through its successful application to a
study involving intravenous administration of bivalirudin to
healthy Chinese volunteers.2. Experimental
2.1. Chemicals and reagents
Bivalirudin (purity499% by HPLC) was kindly provided by
Shenzhen Wanle Drug Research and Development Co. Ltd.
(Shenzhen, PR China). The internal standard (IS), triptorelin
(purity499% by HPLC), was purchased from the National
Institute for the Control of Pharmaceutical and Biological
Products (Beijing, PR China). HPLC grade methanol and
acetonitrile were purchased from Fisher Scientiﬁc (Fair Lawn,
NJ, USA). All other chemicals were commercially available
analytical grade materials used as received. Distilled water
prepared from demineralized water was used throughout
the study.
2.2. Apparatus
LC–MS/MS was performed on an Agilent 1100 Series HPLC
system (Agilent Technologies, Palo Alto, CA, USA) connected
to an API 4000 triple-quadrupole mass spectrometer (Applied
Biosystems MDS Sciex, Ontario, Canada) equipped with an
electrospray ionization (ESI) source. Data acquisition was
controlled by the Analyst Software 1.3 (Applied Biosystems
Sciex, Ontario, Canada).
2.3. Chromatography
Chromatography was performed on a Zorbax 300SB-C18
column (150 mm 4.6 mm i.d., 5 mm particle size, Agilent
Technologies) maintained at 35 1C preceded by a Security Guard
C18 guard column (4 mm 3.0 mm i.d., Phenomenex, USA).
The mobile phase consisted of 0.1% formic acid:methanol
(45:55, v/v) delivered at 0.8 mL/min.
2.4. Mass spectrometry
Tandem mass spectrometry was carried out in the positive
ionization mode using multiple-reaction monitoring (MRM)
of the precursor to product ion transitions at m/z 1091.0-
650.4 for bivalirudin and m/z 656.5-249.3 for the IS.
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curtain gas, gas 1 and gas 2 (all nitrogen) 15, 40 and 50 psi,
respectively; dwell time 200 ms; ion spray voltage 5200 V;
source temperature 450 1C; declustering potential (DP) 63 V
for bivalirudin and 70 V for triptorelin; collision energy (CE)
57 eV for bivalirudin and 73 eV for triptorelin. Low resolution
was set for both Q1 and Q3 mass detection.
2.5. Calibration standards and quality control samples
All solutions were prepared in methanol/water (50:50, v/v).
A stock solution (1 mg/mL) of bivalirudin was diluted to give
standard solutions with concentrations of 1000, 300, 100, 30,
10, 3 and 1 ng/mL. The QC solutions with concentrations of
240, 30 and 3 ng/mL were prepared independently in the same
way. An IS stock solution (1 mg/mL) was used to prepare an
IS working solution (500 ng/mL). All stock and working
solutions were stored at 4 1C when not in use.
2.6. Sample preparation
Frozen plasma samples were thawed at room temperature
prior to analysis. An aliquot of 100 mL plasma, 100 mL
methanol/water (50:50, v/v) (or a standard or QC solution of
bivalirudin), 50 mL 2% aqueous ammonia and 100 mL IS
working solution were added to a 1.5 mL Eppendorf tube,
and then 300 mL acetonitrile was added to precipitate the
proteins. Tubes were vortex-mixed for 30 s and centrifuged at
15,000 rpm for 10 min. The supernatant was transferred to a
2 mL Eppendorf tube followed by 800 mL dichloromethane.
After vortex-mixing for 30 s and centrifugation at 15,000 rpm
for 3 min, an aliquot of 30 mL of the upper aqueous layer was
injected into the LC–MS/MS system. The samples with
concentrations exceeding the ULOQ (1000 ng/mL) were quan-
tiﬁed by dilution of these samples with blank human plasma.
2.7. Adsorption to plastic
Because peptides are known to adsorb on solid-surfaces, the
adsorption of bivalirudin to polypropylene vials was evaluated
using a previously developed protocol [10]. The experiment
involved 7 consecutive transfers of QC solutions and samples
from one polypropylene vial (1.5 mL) to another. Vials were
maintained at 4 1C and every 30 min 500 mL was transferred
from one vial to the other and another 100 mL was removed
for analysis.
2.8. Assay validation
To check the reliability and robust of this method and meet
the guidelines required by the Food and Drug Administration
(FDA) [11], the method was validated in terms of speciﬁcity,
linearity, LLOQ, extraction recovery, matrix effect, accuracy,
precision and stability studies.
2.9. Pharmacokinetic study
The clinical pharmacokinetic study protocol was approved by
the local Ethics Committee and carried out at Peking
University First Hospital, Beijing (China) according to the
guidelines of the International Conference on Harmonization(ICH) [12]. Formal informed consent form was signed by each
volunteer to participate in the study according to the principles
of the Declaration of Helsinki. A total of 9 healthy Chinese male
volunteers were enrolled in this study based on their results of
clinical examinations and medical history. They were not allowed
to consume alcohol or take any other medication during the
study. After a 12 h fast, a group of healthy male volunteers
(n¼9) was administered single i.v. doses (0.5 mg/kg) of bivalir-
udin. Venous blood samples (approximately 1 mL) were col-
lected into heparinized vacuum tubes prior to dosing and at 5,
10, 20, 30, 45, 60, 80, 100, 120 min after the dose. Blood samples
were centrifuged at 15,000 rpm for 5 min at 4 1C and plasma
samples were stored at 80 1C prior to analysis. Pharmacoki-
netic parameters were calculated with non-compartmental model
using a TopFit 2.0 program [13,14].3. Results and discussion
3.1. The physicochemical characteristics of bivalirudin
The amphoteric behavior is one of the most important
physicochemical properties of peptides. The isoelectric point
(pI) of them is not only affected by N-terminal amino and
C-terminal carboxyl groups, but also by the number of basic
AAs (Lys, Arg and His) and acidic AAs (Asp and Glu) in
structures. Bivalirudin comprises 20 amino acids (Phe–Pro–
Arg–Pro–Gly–Gly–Gly–Gly–Asn–Gly–Asp–Phe–Glu–Glu–Ile–
Pro–Glu–Glu–Tyr–Leu), which includes 5 acidic AAs (Glu and
Asp) and 1 basic AA (Arg). The above explanation implies that
the pI of bivalirudin is below 7, though there is no relative
report about bivalirudin’s amphoteric behavior. This result is
signiﬁcant in evaluating the solubility and the ionization
properties for mass spectrometric detection of bivalirudin.
Besides, in the structure there are no methionine, cysteine or
tryptophan residues, which are potentially sensitive to oxida-
tion, indicating that bivalirudin was stable in chemical structure
and did not exhibit chemical changes when exposed to the air.
3.2. Chromatography
To optimize the chromatographic conditions in terms of
robust, sensitivity, run time and peak shape, the following
factors were considered:
3.2.1. Column selection
The 300SB-C18 column used in this study has a large pore size
(300 A˚) which makes it suitable for chromatography of high
molecular weight peptides (42000 Da) such as bivalirudin
(MW 2180.3 Da). Pan et al. [9] used a small pore size (80 A˚)
column with less retention, poorer peak shape and a shorter
column life. In our hands the 300SB-C18 column provided
adequate retention and good peak shape.
3.2.2. Choice of mobile phase
Methanol was used as an organic modiﬁer since it provided
higher sensitivity and better peak shape for bivalirudin
compared to acetonitrile. In positive ion mode, the presence
of a low amount of acid in the mobile phase could improve the
sensitivity of MS signal. Consequently, it was also found that
a low concentration of formic acid (0.1%) in the mobile phase
X.-J. Li et al.4enhanced sensitivity and improved peak shape of bivalirudin.
However, larger concentrations of formic acid or the use of
ammonium acetate was found to suppress the MS signal.
3.2.3. Choice of internal standard
Stable, isotopically labeled analogs of peptides are commonly
used as the IS in the LC–MS/MS assay of peptides. However,
due to the lack of such commercially available analogs of
bivalirudin, some structurally similar compounds (e.g. octreo-
tide and triptorelin) were evaluated as the IS. Subsequently
triptorelin was selected as an IS because it gave similar
extraction recovery and LC retention time to bivalirudin.
3.3. Mass spectrometry
During the early stage of mass spectrometry method develop-
ment, both the electrospray ionization (ESI) and atmosphericFig. 1 Q1 MS full-scan spectra of bpressure chemical ionization (APCI) sources were evaluated.
Results showed that ESI could offer higher sensitivity for the
bivalirudin than APCI under both positive and negative ion
modes. Therefore, ESI was chosen as the ion source for
further study.
The optimization of mass spectrometer conditions was
performed by direct infusion of solutions of bivalirudin and
IS into the ESI source at a ﬂow rate of 20 mL/min. The
positive ion mode was selected since it produced higher
intensity signals than the negative ion mode. Q1 MS full-
scan spectra for bivalirudin (Fig. 1A) contained [Mþ2H]2þ,
[Mþ3H]3þ, [Mþ5H]5þ and [Mþ10H]10þ protonated precursor
ions at m/z 1091.2, 727.8, 437.1 and 219.0, respectively. The
full-scan spectrum was dominated by molecule [Mþ2H]2þ (m/z
1091.2). Bivalirudin product ions at m/z 650.4, 356.2 and 227.1
shown in Fig. 2A correspond to the fragment ions m/z
650.9[y5]
þ, m/z 356.2[a3-NH3]
þ and m/z 227.1[a4-NH3]
2þ,
respectively. The transition at m/z 1091.2-650.4 was selectedivalirudin (A) and triptorelin (B).
Fig. 2 Full-scan product ion spectra of [Mþ2H]2þ ions for bivalirudin (A) and triptorelin (B).
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highest sensitivity using the optimized MS/MS parameters
listed in Section 2.4. Full-scan spectra for IS (Fig. 1B) contained
[MþH]þand [Mþ2H]2þ protonated precursor ions at m/z
1312.2 and 656.5, respectively. The IS product ions at m/z
249.3 and 221.3 shown in Fig. 2B correspond to the fragment
ions m/z 249.3[b2]
þ and m/z 221.3 [y4]
2þ, respectively. The
higher sensitivity of m/z 249.3[b2]
þ clearly indicates the basis of
the choice of the transition at m/z 656.5-249.3 for determina-
tion of the IS.
3.4. Sample preparation
Sample preparation by liquid–liquid extraction (LLE), protein
precipitation (PPT) and re-extraction the supernatant of PPTwas evaluated in the present study. LLE with ethyl acetate
gave poor recovery (o30%). In contrast, PPT using ice-cold
methanol was superior to acetonitrile and gave high recovery
and good peak shapes. However, the LLOQ was high (15 ng/mL)
due to the dilution of analyte in PPT procedure. To improve
the sensitivity, the deproteinated samples were re-extracted
with dichloromethane according to previous studies [15–17],
after centrifugalization bivalirudin and IS in upper aqueous
layer were concentrated. As for extracting a peptide, the pH
is vital for the recovery. In the present study, the re-extraction
recovery was 3 times higher when 2% aqueous ammonia (pH¼9)
was added (Recovery 90%) compared to spiked 1% formic acid
(pH¼2.8). The LLOQ reached 1 ng/mL when 2% aqueous
ammonia was added at re-extraction step, so this method was
used to sample pre-treatment in the present study. The above
Table 1 Sample preparation methods for bivalirudin extraction from human plasma and their extraction effects.
Sample preparation method Extraction effect
LLE with ethyl acetate Low recovery
PPT with ice-cold methanol High recovery (490%) and good peak shape
PPT with acetonitrile High recovery (490%) but poor peak shape
Re-extracted the supernatant of PPT with dichloromethane
(added 1% formic acid)
Recovery about 30%
Re-extracted the supernatant of PPT with dichloromethane
(added 2% aqueous ammonia)
Recovery about 90%, LLOQ can reach 1 ng/mL
Fig. 3 MRM chromatograms for bivalirudin[(A), (B), (C)] and triptorelin(IS)[(A0), (B0), (C0)] in human plasma samples. (A), (A0): a blank
plasma sample; (B), (B0): a blank sample spiked with bivalirudin at the LLOQ (1 ng/mL) and IS (500 ng/mL); (C), (C0): a plasma sample
from a human volunteer 1 h after intravenous administration of bivalirudin (0.5 mg/kg). Max is the maximum of the relative intensity.
X.-J. Li et al.6sample preparation methods for bivalirudin extraction and their
extraction effects are listed in Table 1.
3.5. Adsorption to plastic
The adsorption of peptides to solid-surfaces is a signiﬁcant
issue in the analysis of peptides although few studies have
investigated the phenomenon in detail. In this study the
adsorption of bivalirudin to polypropylene vials was investi-
gated during a series of transfers from one vial to another. No
evidence of adsorption was detected.
3.6. Assay validation
The validation was carried out by analyzing drug free plasma
samples after sample preparation in which standard or QC
solutions replaced the 100 mL methanol/water (50:50, v/v).
3.6.1. Speciﬁcity and selectivity
Typical MRM chromatograms of blank plasma, blank plasma
spiked with bivalirudin at the LLOQ and a study sample 1 hafter i.v. administration of bivalirudin are shown in Fig. 3.
The retention times of bivalirudin and IS were at 2.91 min and
2.47 min, respectively. No signiﬁcant interference from endo-
genous substances was observed in the retention time windows
of bivalirudin and IS.3.6.2. Linearity of calibration curves and LLOQ
Two independent calibration curves based on analyte:IS
peak area ratios were prepared on three separate days and
analyzed by weighted linear regression (1/x2) to validate
the linearity of the method. The LLOQ was the lowest
concentration of analyte that could be determined with
precisionr20% and accuracy720%. The limit of detection
(LOD) was determined as the concentration with signal-to-
noise ratio of 3.
The assay was linear in the concentration range 1–1000 ng/mL
(r40.997) with an LOD of 0.3 ng/mL. A typical standard curve
of a validation intra-day assay (after weighted linear regression
1/x2) is y¼0.00561xþ0.000698, r¼0.9971, where x represents
the plasma concentration (ng/mL) of bivalirudin, and y is the
peak area ratio of bivalirudin to IS.
Quantiﬁcation of bivalirudine in human plasma by LC-MS/MS 73.6.3. Recovery and matrix effect
Recovery of bivalirudin was determined by comparing
peak areas of QC samples with those of blank plasma
samples spiked with standard solutions at corresponding
concentrations. The recoveries of bivalirudin at concentrations
of 3, 30, and 240 ng/mL were 98.673.6%, 99.174.3%, and
97.872.9%, respectively. The recovery of the IS was
97.375.3%.
Matrix effects were evaluated by comparing peak areas of
post-extraction blank plasma spiked with QC solutions with
peak areas of post-extraction aqueous blank samples spiked
with QC solutions. In the study of matrix effects, concentra-
tions of bivalirudin and IS were 94.2%, 95.8% and 97.0% of
nominal concentrations respectively, indicating that no sig-
niﬁcant signal suppression or enhancement occurred in the
ionization of bivalirudin or IS.
3.6.4. Precision and accuracy
Intra- and inter-day precision (as relative standard deviation,
RSD) and accuracy (as relative error, RE) were assessed by
assay of QC samples (n¼6) on three separate days.
Table 2 summarizes the accuracy and precision data based
on analysis of QC samples. Intra- and inter-day precisions
were 0.62–2.92% and 1.84–3.36%, respectively with accuracy
of 99.6–100.5%.
3.6.5. Stability
Stability of bivalirudin was tested by analysis of QC samples
under the following conditions: long-term stability in plasmaTable 2 Precision and accuracy for the determination of bivaliru
Nominal concentration
(ng/mL)
Calculated concentration
(ng/mL)
In
3.0 2.9970.07 2.9
30.0 29.970.5 0.6
240.0 241.179.0 2.6
aData are based on assay of 6 replicates on 3 different days.
Table 3 Stability of bivalirudin under various storage condition
Storage conditions Nominal con
(ng/mL)
Room temperature for 4 h 3.0
30.0
240.0
Processed QC samples under autosampler conditions 3.0
30.0
240.0
Three freeze/thaw cycles 3.0
30.0
240.0
Storage at 80 1C for 75 days 3.0
30.0
240.0samples maintained at 80 1C for 75 days; short-term stability
in plasma samples maintained at 25 1C for 4 h; in processed
samples in autosampler vials for 7 h; and after three freeze/
thaw cycles (20 to 25 1C). Stability of stock solutions stored
at 4 1C for one week was also assessed.
In the present study, bivalirudin was shown to be stable
under all the storage conditions evaluated with mean recov-
eries of 93.7–101.4% of the nominal concentrations (Table 3).
Stock solutions of bivalirudin and IS stored for one week at
4 1C were comparable to freshly prepared ones.
3.7. Pharmacokinetic study
The plasma concentration–time proﬁle of bivalirudin after a
single i.v. dose (0.5 mg/kg) in 9 healthy volunteers is illustrated
in Fig. 4. Corresponding pharmacokinetic parameters are
listed in Table 4. After i.v. administration, the concentration
of bivalirudin was eliminated with a half-life (t1/2) of
20.271.7 min and the clearance 5.870.9 mL/min/kg. The
area under the plasma concentration–time curve (AUC0t)
was 88,630716,690 ng min/mL and the volume of distribution
(Vd) of bivalirudin was 0.1770.02 L/kg. These pharmacoki-
netic parameters are similar to those reported by Pan et al. [9]
and in other previous studies [6,8,18].4. Conclusion
The present LC–MS/MS method is a more sensitive, versatile
and rapid assay for the determination of bivalirudin in humandin in human plasmaa.
tra-day precision
RSD (%)
Inter-day precision
RSD (%)
Accuracy
RE (%)
2 2.35 0.3
2 1.84 0.4
3 3.36 0.5
s (n¼3).
centration Calculated concentration
(ng/mL)
RSD (%) RE (%)
3.0470.10 4.72 1.44
29.870.5 1.51 0.78
243.078.1 3.35 1.40
2.9570.10 2.76 1.56
29.970.9 2.85 0.44
241.0711.7 4.85 0.30
2.9970.10 1.84 0.22
29.771.3 4.38 0.89
239.074.5 1.89 6.30
2.9770.10 2.99 0.22
29.870.3 1.01 0.67
239.079.8 4.12 0.40
Fig. 4 Mean plasma concentration–time proﬁle of bivalirudin
after a single intravenous dose of 0.5 mg/kg (Data are mean7SD,
n¼9.).
Table 4 Pharmacokinetic parameters for bivalirudin in
healthy volunteers after a single intravenous dose (0.5 mg/kg).
Parameters Mean7SDa
AUC0t (ng min/mL) 88,630716,690
AUC0N (ng min/mL) 90,700718,670
t1/2 (min) 20.271.7
MRT0t (min) 24.072.0
CL (mL/min/kg) 5.870.9
Vd (L/kg) 0.1770.02
aData are mean7SD, n¼9.
X.-J. Li et al.8plasma with a run time of only 3.5 min. The method only
needs a simple re-extraction sample pre-treatment, no inter-
ference caused by endogenous compounds was observed.
More than 150 samples could be assayed daily, including
sample extraction, data collection and processing. The LLOQ
was 1 ng/mL and LOD was 0.3 ng/mL, with only 100 mL of
plasma sample in this method, which greatly reduces the
distress and improves the compliance of the volunteers. The
assay was successfully applied to a clinical pharmacokinetic
study of bivalirudin in healthy volunteers, which indicate that
it is suitable for analysis of large batches of bivalirudin
biological samples.
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